230 related articles for article (PubMed ID: 32900375)
1. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC
Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375
[TBL] [Abstract][Full Text] [Related]
2. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
[TBL] [Abstract][Full Text] [Related]
3. Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity.
Ysselstein D; Joshi M; Mishra V; Griggs AM; Asiago JM; McCabe GP; Stanciu LA; Post CB; Rochet JC
Neurobiol Dis; 2015 Jul; 79():150-63. PubMed ID: 25931201
[TBL] [Abstract][Full Text] [Related]
4. Toxic effects of human and rodent variants of alpha-synuclein in vivo.
Landeck N; Buck K; Kirik D
Eur J Neurosci; 2017 Feb; 45(4):536-547. PubMed ID: 27893183
[TBL] [Abstract][Full Text] [Related]
5. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
6. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW
Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693
[TBL] [Abstract][Full Text] [Related]
7. Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.
Luna E; Decker SC; Riddle DM; Caputo A; Zhang B; Cole T; Caswell C; Xie SX; Lee VMY; Luk KC
Acta Neuropathol; 2018 Jun; 135(6):855-875. PubMed ID: 29502200
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
[TBL] [Abstract][Full Text] [Related]
9. Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
Ruf VC; Nübling GS; Willikens S; Shi S; Schmidt F; Levin J; Bötzel K; Kamp F; Giese A
ACS Chem Neurosci; 2019 Mar; 10(3):1649-1659. PubMed ID: 30605594
[TBL] [Abstract][Full Text] [Related]
10. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease.
Tönges L; Szegö EM; Hause P; Saal KA; Tatenhorst L; Koch JC; D Hedouville Z; Dambeck V; Kügler S; Dohm CP; Bähr M; Lingor P
Front Aging Neurosci; 2014; 6():239. PubMed ID: 25309425
[TBL] [Abstract][Full Text] [Related]
13. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
[TBL] [Abstract][Full Text] [Related]
14. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models.
Vinueza-Gavilanes R; Bravo-González JJ; Basurco L; Boncristiani C; Fernández-Irigoyen J; Santamaría E; Marcilla I; Pérez-Mediavilla A; Luquin MR; Vales A; González-Aseguinolaza G; Aymerich MS; Aragón T; Arrasate M
Neurobiol Dis; 2023 Jul; 183():106166. PubMed ID: 37245833
[TBL] [Abstract][Full Text] [Related]
16. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
[TBL] [Abstract][Full Text] [Related]
17. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
18. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
19. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
20. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.
Xilouri M; Vogiatzi T; Vekrellis K; Park D; Stefanis L
PLoS One; 2009; 4(5):e5515. PubMed ID: 19436756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
